Ivabradine Dosing and Adjustments
The recommended starting dose of ivabradine is 5 mg twice daily with food, titrated after 2 weeks to achieve a resting heart rate of 50-60 bpm, with a maximum dose of 7.5 mg twice daily; in patients with severe hepatic impairment, ivabradine is contraindicated, and concomitant use with strong CYP3A4 inhibitors must be avoided. 1
Standard Dosing Protocol
Initial Dosing
- Start at 5 mg twice daily with food in most adult patients 1, 2, 3
- For older adults or those at higher risk: initiate at 2.5 mg twice daily 4
- In patients with conduction defects or risk of hemodynamic compromise from bradycardia: begin at 2.5 mg twice daily before dose escalation 1
Titration Schedule
Assess heart rate after 2 weeks and adjust according to the following algorithm 1:
- Heart rate >60 bpm: Increase by 2.5 mg twice daily (maximum 7.5 mg twice daily)
- Heart rate 50-60 bpm: Maintain current dose
- Heart rate <50 bpm or symptomatic bradycardia: Decrease by 2.5 mg twice daily; if already on 2.5 mg twice daily, discontinue therapy
The maintenance dose is typically 7.5 mg twice daily, though this should be adjusted based on individual heart rate response and tolerability 2, 3.
Special Populations and Dose Adjustments
Hepatic Impairment
Ivabradine is absolutely contraindicated in severe hepatic impairment 2, 3, 1. The drug should be avoided in patients with advanced liver disease 4. No specific dose adjustments are provided for mild-to-moderate hepatic impairment in the guidelines, but caution is warranted.
Strong CYP3A4 Inhibitors
Concomitant use with strong CYP3A4 inhibitors is contraindicated 1. These include 2, 3:
- Azole antifungals: itraconazole, ketoconazole, posaconazole, voriconazole
- Protease inhibitors: boceprevir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, telaprevir
- Macrolide antibiotics: clarithromycin
Avoid concurrent use with moderate CYP3A4 inhibitors including diltiazem, verapamil, and grapefruit juice 2, 3, 2, 3. The combination of ivabradine with non-dihydropyridine calcium channel blockers is specifically not recommended 5.
CYP3A4 Inducers
Avoid use with strong CYP3A4 inducers including carbamazepine, phenytoin, rifampin, and St. John's wort, as these will reduce ivabradine efficacy 2, 3.
Clinical Context and Indications
Heart Failure with Reduced Ejection Fraction
Ivabradine is indicated for HFrEF patients with 4:
- LVEF ≤35%
- Symptomatic despite guideline-directed medical therapy
- Resting heart rate >70 bpm (some regulatory authorities use 70-77 bpm threshold)
- Sinus rhythm
- Either on maximally tolerated beta-blocker doses or beta-blocker intolerant
The Canadian guidelines note that ivabradine is well tolerated in older adults and can be initiated at 2.5 mg twice daily in this population 4.
Important Contraindications Beyond Hepatic Impairment
Ivabradine is contraindicated in 1:
- Acute decompensated heart failure
- Clinically significant hypotension (BP <90/50 mm Hg) 2, 3
- Sick sinus syndrome, sinoatrial block, or 3rd-degree AV block (unless pacemaker present)
- Pacemaker dependence
- Clinically significant bradycardia
Common Pitfalls and Monitoring
Key Monitoring Parameters
- Assess heart rate at 2 weeks after initiation or dose change to guide titration 1
- Monitor for atrial fibrillation regularly, as ivabradine increases AF risk (5.0% vs 3.9% per patient-year with placebo) 1
- Discontinue if atrial fibrillation develops, as ivabradine requires sinus rhythm for efficacy 1
- Watch for bradycardia: occurred in 6.0% per patient-year in trials (2.7% symptomatic) 1
Adverse Effects
The most common side effect is phosphenes (visual brightness phenomena), reported in approximately 3% of patients, though usually transient 2. No negative effects on blood pressure, myocardial contractility, or renal function occur 4.
Drug Interactions to Remember
Amiodarone: Avoid concurrent use as amiodarone is a moderate CYP3A4 inhibitor and the combination increases ivabradine levels 2. Digoxin: No dose adjustment needed, but monitor as both affect heart rate 2. Proton pump inhibitors (omeprazole, lansoprazole): No pharmacokinetic interaction demonstrated 6.